Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02879643 Phase I Dexamethasone + Methotrexate + Pegaspargase + Vincristine sulfate liposome Dexamethasone + Mercaptopurine + Methotrexate + Vincristine sulfate liposome Dexamethasone + Methotrexate + Mitoxantrone + Pegaspargase + Vincristine sulfate liposome Vincristine Sulfate Liposome Injection (Marqibo) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL Unknown status USA | CAN | AUS 0
NCT03643276 Phase III Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Mercaptopurine + Methotrexate Bortezomib + Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Pegaspargase + Vincristine Sulfate + Vindesine Blinatumomab + Cyclophosphamide + Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab Cytarabine + Daunoxome + Fludarabine + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate Asparaginase Erwinia chrysanthemi Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Recruiting SVK | ITA | ISR | DEU | CZE | CHE | AUT | AUS 0
NCT03860844 Phase II Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Terminated USA | SWE | NOR | NLD | ITA | HUN | GRC | FRA | DNK | DEU | BRA | ARG 4